EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Revenue

In the fiscal year ending March 31, 2026, EQL Pharma AB had annual revenue of 432.66M SEK with 15.83% growth. EQL Pharma AB had revenue of 120.17M in the quarter ending March 31, 2026, with 6.10% growth.

• Revenue: 432.66M
• Revenue Growth: +15.83%
• P/S Ratio: 1.41
• Revenue / Employee: 7.21M
• Employees: 60
• Market Cap: 608.31M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	432.66M	59.15M	15.83%
Mar 31, 2025	373.52M	109.35M	41.39%
Mar 31, 2024	264.17M	4.26M	1.64%
Mar 31, 2023	259.91M	-149.84M	-36.57%
Mar 31, 2022	409.75M	230.61M	128.73%
Mar 31, 2021	179.14M	107.11M	148.71%
Mar 31, 2020	72.03M	22.27M	44.77%
Mar 31, 2019	49.76M	21.17M	74.08%
Mar 31, 2018	28.58M	7.05M	32.72%
Dec 31, 2017	21.54M	-6.67M	-23.63%
Dec 31, 2016	28.20M	1.33M	4.94%
Dec 31, 2015	26.87M	9.28M	52.78%
Dec 31, 2014	17.59M	-4.58M	-20.67%
Dec 31, 2013	22.17M	5.50M	32.99%
Dec 31, 2012	16.67M	4.91M	41.69%
Dec 31, 2011	11.77M	-	-

Data Source: Fiscal.ai Last updated: May 8, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error